Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BBLG 
Bone Biologics Corp (BBLG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: BBLG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22.5
1 Year Target Price $22.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -81.26% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.61M USD | Price to earnings Ratio - | 1Y Target Price 22.5 |
Price to earnings Ratio - | 1Y Target Price 22.5 | ||
Volume (30-day avg) 1 | Beta 0.51 | 52 Weeks Range 1.86 - 10.08 | Updated Date 11/6/2025 |
52 Weeks Range 1.86 - 10.08 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -21.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.63% | Return on Equity (TTM) -88.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -2062555 | Price to Sales(TTM) - |
Enterprise Value -2062555 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.13 | Shares Outstanding 1795260 | Shares Floating 1638983 |
Shares Outstanding 1795260 | Shares Floating 1638983 | ||
Percent Insiders 8.31 | Percent Institutions 0.03 |
Upturn AI SWOT
Bone Biologics Corp
Company Overview
History and Background
Bone Biologics Corp (BBLG) is focused on bone regeneration. Founded to develop and commercialize osteopromotive technology for spinal fusion procedures. It has evolved through clinical trials and regulatory approvals.
Core Business Areas
- Spinal Fusion: Developing and commercializing NBMP for spinal fusion procedures to enhance bone regeneration.
Leadership and Structure
The company has a management team and a board of directors overseeing its operations. Details on specific individuals would require up-to-date research.
Top Products and Market Share
Key Offerings
- NBMP (NELL-1/BMP-2 Mimetic Protein): NBMP is Bone Biologics' primary product, designed to promote bone regeneration in spinal fusion procedures. Market share data is difficult to ascertain precisely, but is very small given the company's size and stage of development. Main competitors include Medtronic (MDT), Johnson & Johnson (JNJ), and Stryker (SYK) who offer BMP-2 based products and other spinal fusion solutions.
Market Dynamics
Industry Overview
The spinal fusion market is substantial and growing due to aging populations and increasing incidence of spinal disorders. The market includes bone graft substitutes, interbody devices, and biologics.
Positioning
Bone Biologics aims to compete with established companies by offering a novel osteopromotive protein that may have advantages over existing BMP-2 products. This advantage would be based on safety and/or efficacy.
Total Addressable Market (TAM)
The global spinal fusion market is estimated in the billions of dollars. Bone Biologics is positioned to capture a portion of this TAM with its NBMP technology, dependent on clinical success and market adoption. TAM is difficult to predict due to the nature of the product being in development and requiring FDA approval.
Upturn SWOT Analysis
Strengths
- Proprietary NBMP technology
- Potential for improved safety profile compared to BMP-2
- Focus on a large and growing market
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Competition from established players
Opportunities
- Partnerships with larger companies
- Expansion into other bone regeneration applications
- Positive clinical trial results
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and emerging technologies
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Johnson & Johnson (JNJ)
- Stryker (SYK)
Competitive Landscape
Bone Biologics faces intense competition from larger, established companies with greater resources. Its success depends on demonstrating the superiority of its NBMP technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth requires accessing the company's SEC filings.
Future Projections: Future projections require analyst estimates and are not provided in this response.
Recent Initiatives: Recent initiatives require access to company press releases and SEC filings.
Summary
Bone Biologics Corp. is a small company in the competitive field of bone regeneration with a novel approach for spinal fusion. Its success hinges on the outcome of clinical trials and ability to attract partnerships. The company's financial position and regulatory hurdles are key risks to consider. NBMP must show to be safer and/or more effective than current solutions in order to gain market share. The company is considered to be a high risk, high reward investment.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is approximate and may vary. Financial data requires accessing the company's most recent SEC filings. Always consult with a qualified financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bone Biologics Corp
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2016-03-31 | CEO & President Mr. Jeffrey Frelick | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2 | Website https://www.bonebiologics.com |
Full time employees 2 | Website https://www.bonebiologics.com | ||
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.